Nektar Therapeutics (NKTR) Current Leases (2016 - 2025)
Historic Current Leases for Nektar Therapeutics (NKTR) over the last 13 years, with Q3 2025 value amounting to $22.2 million.
- Nektar Therapeutics' Current Leases rose 315.76% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 315.76%. This contributed to the annual value of $19.9 million for FY2024, which is 316.22% up from last year.
- Per Nektar Therapeutics' latest filing, its Current Leases stood at $22.2 million for Q3 2025, which was up 315.76% from $22.0 million recorded in Q2 2025.
- Nektar Therapeutics' 5-year Current Leases high stood at $22.2 million for Q3 2025, and its period low was $15.8 million during Q1 2021.
- Its 5-year average for Current Leases is $19.4 million, with a median of $19.3 million in 2023.
- Per our database at Business Quant, Nektar Therapeutics' Current Leases skyrocketed by 2533.96% in 2021 and then crashed by 555.69% in 2023.
- Quarter analysis of 5 years shows Nektar Therapeutics' Current Leases stood at $17.4 million in 2021, then rose by 7.03% to $18.7 million in 2022, then increased by 3.17% to $19.3 million in 2023, then rose by 3.16% to $19.9 million in 2024, then rose by 11.65% to $22.2 million in 2025.
- Its Current Leases stands at $22.2 million for Q3 2025, versus $22.0 million for Q2 2025 and $21.8 million for Q1 2025.